FDA 483 OBSERVATION · #70 OF 1,945 MOST-CITED

Specifications - finished dietary supplement

FDA cited this observation 363 times across 356 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Foods363
BY FISCAL YEAR
FY20273
FY2026168
FY2025170
FY202422

What this observation means, and how to comply

SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.

21 CFR 111.70(e)

A dietary-supplement manufacturer did not establish adequate specifications for the finished batch of dietary supplement, so there was no defined standard the finished product had to meet for identity, purity, strength, composition, and limits on contaminants.

Why FDA writes it — The finished-product specification is the definition of an acceptable dietary supplement. Without it, the manufacturer cannot judge whether a batch is acceptable — release becomes arbitrary, and label claims are unsupported.

HOW TO COMPLY
  • Establish product specifications for the identity, purity, strength, and composition of the finished batch of dietary supplement, and for limits on contaminants.
  • Establish specifications that ensure the label claims are met.
  • Verify that finished batches meet the specifications (or, with a documented exemption, meet the requirements for exemption).
  • Reject batches that do not meet specifications.
WHY FIRMS GET CITED
  • No finished-product specifications, so release has no acceptance standard.
  • Specifications that do not actually ensure the label claims are met.
PROFESSIONAL · REMEDIATION PLAYBOOK · SPEQ SYNTHESIS

How to close this finding — and stop it recurring

CHECKING ACCESS

Checking your access…

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 2.2× the rate of the average FDA-cited firm (16.9% vs 7.8%), across 356 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your access…

How FDA worded it — real examples

You did not establish product specifications for purity, strength and limits on contamination.

TopGum Pharma, Inc. · Copiague, New York · Foods · 2026-10-30

You did not establish product specifications for purity, strength and composition.

Nature's Value Inc. · Coram, New York · Foods · 2026-10-15

You did not establish product specifications for identity, purity, strength, composition and limits on contamination.

Nutralife Biosciences, Inc. · Coconut Creek, Florida · Foods · 2026-10-01

You did not establish product specifications for identity, purity, strength, composition and limits on contamination.

Remedy's Health Food, Inc. · Key Largo, Florida · Foods · 2026-09-22

You did not establish product specifications for identity, purity, strength, composition and limits on contamination.

Natural Solution Laboratories, Inc. · Gravette, Arkansas · Foods · 2026-09-22

You did not establish product specifications for identity, purity, strength and limits on contamination.

NCAQCO, LLC · Chesterfield, Missouri · Foods · 2026-09-18

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Food industry →

Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →